新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 礼来 » Celgene, 礼来与GE Ventures携手支持纽约生物技术公司孵化

Celgene, 礼来与GE Ventures携手支持纽约生物技术公司孵化

来源:生物谷 2013-12-05 19:46

2013年12月5日讯 /生物谷BIOON/ --最近生命技术产业领域三个重要参与者Celgene, 礼来与GEVentures携手提供1亿美元的投资用于支持纽约市的生物技术公司孵化,按计划这笔资金将用于资助最多20家生物技术公司。礼来公司的研发主管Jan Lundberg 表示药物的早期研究在药物开发中有着重要地位,然而最近几年投入在这一领域的经费不断缩减,这也是为什么礼来作出这种投资的原因所在。众所周知,纽约在生物技术领域的科研实力十分强大,然而它却未成为像波士顿、旧金山或者英国的伦敦-牛津-剑桥三角那样的生物产业中心。现在,数家制药巨头开始布局进入纽约,如罗氏公司就将其在曼哈顿的研发中心迁到该处,这也无形中给纽约跻身美国乃至世界生物医药研发中心提供了契机。(生物谷Bioon.com)

详细英文报道:

Three big players in the life sciences industry--Celgene ($CELG), Eli Lilly ($LLY) and GE Ventures--are chipping in to help fund a $100 million venture fund that will be used to launch up to 20 new biotech companies in New York City, adding some fuel to a small but growing fire of R&D efforts in the Big Apple.

The Bloomberg administration took the lead on this project, according to The Wall Street Journal, seeding the fund with $10 million and teaming up with the industry partners. Now they're looking for a venture player to kick in $50 million on top of the $40 million promised by Celgene, Lilly and GE and take the lead in finding 15 to 20 new biotechs to back.

Lilly R&D chief Jan Lundberg says that the scarcity of startup funds helped persuade the pharma giant to participate.

"It's quite unfortunate that early-stage investment has been reduced over time from venture capital companies and that's the reason that big pharma companies like Lilly are interested in this area," Lundberg told the Journal.

New York has a stellar reputation in scientific research, but has never come close to developing a biotech hub that can rival Boston and San Francisco and the U.K. triangle in London-Oxford-Cambridge. Roche ($RHHBY) gave the city a big boost when it decided to move a group of 250 pRED survivors from the Nutley, NJ, shutdown to a research hub in Manhattan, neighboring Lilly's ImClone subsidiary at the Alexandria Center for Life Science on the East Side of Manhattan.

Life science backers in the area have long complained that the lack of venture capital has been one of the most important challenges faced in creating a hub, and now the big players are taking direct action to remedy that issue.

 

本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库